Each student registering to present at the Summit may make ONLY ONE presentation during the daytime sessions: i.e., only one poster or talk or panel discussion or screening, etc. With up to 300 ...

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology ...

All titles, abstracts, photos and YouTube presentations will need your research mentor’s approval prior to submitting your abstract. The abstract will be open to public viewing. Submit your abstract ...

Pharvaris, a biopharmaceutical company based in Zug, Switzerland, announced the acceptance of multiple abstracts for presentation at three significant upcoming congresses focusing on angioedema, ...

Accepted Abstract is a Sub-Study in RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial and Explores the TAMP™ Therapy Platform’s Potential to Increase Local Drug Potency and Reduce Systemic ...

SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (VIR) today announced that five abstracts highlighting new data from the Company’s broad hepatitis portfolio addressing both ...

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced eleven abstracts accepted for presentation at the 2021 American Society of Clinical ...

Advaxis, Inc.Diana Moore, 609-452-9814Director, Investor Relations & Business Development ., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced ...

BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of ...